Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SGMO's Cash to Debt is ranked higher than
76% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. SGMO: No Debt )
SGMO' s 10-Year Cash to Debt Range
Min: 25.33   Max: No Debt
Current: No Debt

Equity to Asset 0.86
SGMO's Equity to Asset is ranked higher than
88% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SGMO: 0.86 )
SGMO' s 10-Year Equity to Asset Range
Min: 0.77   Max: 0.97
Current: 0.86

0.77
0.97
Interest Coverage No Debt
SGMO's Interest Coverage is ranked higher than
98% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGMO: No Debt )
SGMO' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 26.57
M-Score: -2.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -110.66
SGMO's Operating margin (%) is ranked higher than
67% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. SGMO: -110.66 )
SGMO' s 10-Year Operating margin (%) Range
Min: -1114.07   Max: -50.32
Current: -110.66

-1114.07
-50.32
Net-margin (%) -110.32
SGMO's Net-margin (%) is ranked higher than
66% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. SGMO: -110.32 )
SGMO' s 10-Year Net-margin (%) Range
Min: -1050.8   Max: -48.73
Current: -110.32

-1050.8
-48.73
ROE (%) -21.87
SGMO's ROE (%) is ranked higher than
71% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. SGMO: -21.87 )
SGMO' s 10-Year ROE (%) Range
Min: -96.5   Max: -13.55
Current: -21.87

-96.5
-13.55
ROA (%) -18.90
SGMO's ROA (%) is ranked higher than
71% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. SGMO: -18.90 )
SGMO' s 10-Year ROA (%) Range
Min: -81.47   Max: -13.15
Current: -18.9

-81.47
-13.15
ROC (Joel Greenblatt) (%) -1899.43
SGMO's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. SGMO: -1899.43 )
SGMO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4606.92   Max: -423.3
Current: -1899.43

-4606.92
-423.3
Revenue Growth (%) -2.20
SGMO's Revenue Growth (%) is ranked higher than
73% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. SGMO: -2.20 )
SGMO' s 10-Year Revenue Growth (%) Range
Min: -38   Max: 68.7
Current: -2.2

-38
68.7
EBITDA Growth (%) -4.50
SGMO's EBITDA Growth (%) is ranked higher than
78% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. SGMO: -4.50 )
SGMO' s 10-Year EBITDA Growth (%) Range
Min: -23.7   Max: 106.7
Current: -4.5

-23.7
106.7
EPS Growth (%) -4.40
SGMO's EPS Growth (%) is ranked higher than
80% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. SGMO: -4.40 )
SGMO' s 10-Year EPS Growth (%) Range
Min: -25.2   Max: 184.4
Current: -4.4

-25.2
184.4
» SGMO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

SGMO Guru Trades in Q1 2013

Jim Simons 209,900 sh (New)
Jean-Marie Eveillard 300,000 sh (New)
» More
Q2 2013

SGMO Guru Trades in Q2 2013

Paul Tudor Jones 17,200 sh (New)
Jean-Marie Eveillard 424,350 sh (+41.45%)
Jim Simons 17,000 sh (-91.9%)
» More
Q3 2013

SGMO Guru Trades in Q3 2013

Jean-Marie Eveillard 847,550 sh (+99.73%)
Jim Simons Sold Out
Paul Tudor Jones 13,600 sh (-20.93%)
» More
Q4 2013

SGMO Guru Trades in Q4 2013

Steven Cohen 1,121,300 sh (New)
Jean-Marie Eveillard 847,550 sh (unchged)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SGMO

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-09-30 Add 99.73%0.01%$7.92 - $11.28 $ 14.2643%847550
Jean-Marie Eveillard 2013-06-30 Add 41.45%$7.31 - $10.65 $ 14.2664%424350
Jean-Marie Eveillard 2013-03-31 New Buy0.01%$6.01 - $10.8 $ 14.2660%300000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.30
SGMO's P/B is ranked lower than
55% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. SGMO: 7.30 )
SGMO' s 10-Year P/B Range
Min: 1.34   Max: 11.7
Current: 7.3

1.34
11.7
P/S 33.00
SGMO's P/S is ranked lower than
73% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. SGMO: 33.00 )
SGMO' s 10-Year P/S Range
Min: 4.84   Max: 129.75
Current: 33

4.84
129.75
EV-to-EBIT 0.30
SGMO's EV-to-EBIT is ranked higher than
96% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. SGMO: 0.30 )
SGMO' s 10-Year EV-to-EBIT Range
Min: 12.7   Max: 34.2
Current: 0.3

12.7
34.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.00
SGMO's Price/Net Cash is ranked lower than
54% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. SGMO: 12.00 )
SGMO' s 10-Year Price/Net Cash Range
Min: 1.48   Max: 11.67
Current: 12

1.48
11.67
Price/Net Current Asset Value 11.60
SGMO's Price/Net Current Asset Value is ranked lower than
52% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. SGMO: 11.60 )
SGMO' s 10-Year Price/Net Current Asset Value Range
Min: 1.45   Max: 11.29
Current: 11.6

1.45
11.29
Price/Tangible Book 7.50
SGMO's Price/Tangible Book is ranked lower than
54% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. SGMO: 7.50 )
SGMO' s 10-Year Price/Tangible Book Range
Min: 1.37   Max: 7.27
Current: 7.5

1.37
7.27
Price/Median PS Value 1.40
SGMO's Price/Median PS Value is ranked higher than
56% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. SGMO: 1.40 )
SGMO' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 4.2
Current: 1.4

0.36
4.2
Earnings Yield (Greenblatt) 323.20
SGMO's Earnings Yield (Greenblatt) is ranked higher than
93% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. SGMO: 323.20 )
SGMO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.9   Max: 631.9
Current: 323.2

2.9
631.9
Forward Rate of Return (Yacktman) -2.71
SGMO's Forward Rate of Return (Yacktman) is ranked higher than
82% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. SGMO: -2.71 )
SGMO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.4   Max: 91.5
Current: -2.71

-2.4
91.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GBY.Germany
Sangamo BioSciences, Inc., was incorporated in June 1995 in the state of Delaware. It is a clinical stage biopharmaceutical company engaged in the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. The main focus for the company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. Its lead ZFP Therapeutic, SB-728-T, a ZFN-modified autologous T-cell product for the treatment of HIV/AIDS, is the first therapeutic application of its ZFN technology and is being evaluated in an ongoing Phase 2 and two Phase 1/2 clinical trials. It has preclinical ZFP Therapeutic development programs in hemophilia and Parkinson's disease. In addition, it has research stage programs in other monogenic diseases; genetic conditions that result from a defect in a single gene, including hemoglobinopathies such as sickle cell anemia, lysosomal storage diseases and certain immunodeficiencies. On January 31, 2012, the Company entered into a collaboration and license agreement with Shire AG (Shire), pursuant to which it will collaborate with Shire to research, develop and commercialize human therapeutics for hemophilia and other monogenic diseases based on its ZFP technology. It has a license agreement with the research reagent company Sigma-Aldrich Corporation (Sigma). Sigma has the exclusive rights to develop and market high value laboratory research reagents based upon its ZFP technology as well as ZFP-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals. Sigma is marketing ZFN-derived gene editing tools under the trademark CompoZr and is selling transgenic animals through its SAGETM Labs business unit. The Company has a license agreement with Dow AgroSciences, LLC (DAS), a wholly owned subsidiary of Dow Chemical Corporation. Under the agreement, it has provided DAS with access to its ZFP technology and the exclusive rights to use it to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. DAS markets its ZFN technology under the trademark EXZACTTM Precision Technology. The Company has retained rights to use plants or plant-derived products to deliver ZFP TFs or ZFNs into human or animals for diagnostic, therapeutic, or prophylactic purposes. It faces intense competition from other companies for collaborative arrangements with pharmaceutical and biotechnology companies; for establishing relationships with academic and research institutions; and for licenses to proprietary technology. Its therapeutic or pharmaceutical products undergoes rigorous preclinical testing and clinical trials in humans and an extensive regulatory clearance process implemented by the U.S. Food and Drug Administration (FDA) under the federal Food, Drug and Cosmetic Act.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide